TECENTRIQ (atezolizumab) authorized for Canadians with early non-small cell lung cancer

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 14, 2022, Health Canada has authorized TECENTRIQ® (atezolizumab) as - Click here if this is your press release! - Travel News | eTurboNews | eTN

Related Keywords

Canada , Quebec , Canadians , Loredana Regep , Shem Singh , Peter Glazier , Lung Health Foundation , Roche Limited Canada , Regulatory Affairs , Health Canada , Hoffmann La Roche Limited , Roche Canada , Programmed Death , Executive Director Lung Cancer , Executive Vice President , Lung Health , Vice President , Hoffmann La Roche ,